Verve Therapeutics Surges to 61st in Daily Rankings with $906 Million Turnover Amid Eli Lilly Acquisition

On June 17, 2025, Verve Therapeutics (VERV) experienced a significant surge in trading volume, with a turnover of $906 million, marking a 4037.68% increase from the previous day. This substantial rise in trading volume placed Verve at the 61st position in the daily stock market rankings. The stock price of Verve Therapeutics soared by 81.50%, marking its second consecutive day of gains, with a total increase of 84.74% over the past two days.

Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion. The deal includes an upfront payment of nearly $1 billion, with an additional $300 million contingent on Verve achieving specific clinical milestones. This acquisition is part of Lilly's strategic push into gene editing and cardiovascular care, aiming to integrate Verve's pipeline of gene therapies into its portfolio.

Verve Therapeutics' CEO, Dr. Sekar Kathiresan, highlighted the company's mission to revolutionize cardiovascular disease treatment through gene editing. Founded with the goal of transitioning from chronic care to a one-dose treatment future, Verve has made significant progress in developing in vivo gene editing products, with two currently in clinical trials. The acquisition by Eli Lilly is expected to accelerate the development and commercialization of these innovative therapies.

Verve's lead product, VERVE-102, is currently undergoing a Phase 1b clinical trial and has received Fast Track designation from the U.S. Food and Drug Administration. This designation is intended to expedite the development and review of drugs that treat serious conditions and fill an unmet medical need. The potential acquisition by Eli Lilly is expected to close in the third quarter of this year, subject to regulatory approvals and other customary closing conditions.